Sonoporation is an established method whereby acoustically stimulated microbubbles create pores in the endothelium to promote the delivery of nucleic acids and other macromolecules through the vasculature. In this presentation, we describe the development of polyplex-microbubbles to enhance delivery and intracellular trafficking to target cells beyond the endothelium following sonoporation. Our design combines the tissue targeting capability of microbubbles with the cellular targeting capability of polyplexes, which are self-assembled particles comprising nucleic acids and a cationic polymer. The first purpose of the cationic polymer (polyethylenimine, PEI) is to condense and protect the nucleic acids on the microbubble surface as it travels in circulation from the site of injection to the target tissue. Polyethylene glycol (PEG) is conjugated to the PEI to reduce immunogenicity. Ultrasound is applied to the target tissue to fragment the microbubbles and release the polyplexes and to porate the endothelium, allowing the polyplexes to extravasate. The second purpose of PEI is to promote endocytotic uptake and subsequent endosomal escape of the nucleic acids into the cytoplasm by the so-called "proton-sponge" effect. Here, we describe polyplex-microbubble fabrication and characterization, as well as in vivo testing. Our results indicate the promise of this design for cancer gene therapy.
INTRODUCTION
Systemic gene delivery is still largely inefficient due to rapid clearance of nucleic acids from the bloodstream via the mononuclear phagocyte system (MPS) and enzymatic degradation (Nishikawa and Huang, 2001) . Several novel microbubble formulations have been developed in order to improve systemic gene transfection efficiency by loading plasmid DNA or oligonucleotides onto the microbubble surface. Deposition methods include (i) direct physical incorporation of the DNA into the microbubble shell during fabrication (Frenkel et al., 2002; Seemann et al., 2002) , (ii) the use of cationic lipids incorporated into the microbubble shell to electrostatically bind DNA (Christiansen et al., 2003) , (iii) deposition of single (Lentacker et al., 2006) or multi-layers (Borden et al., 2007) of cationic polymer on the microbubble shell to electrostatically bind DNA, (iv) covalent linking of DNA-nanoparticle carriers (Vandenbroucke et al., 2008) and (v) use of complementary DNA strands to load nanoparticles (Lozano et al.) . Physical attachment to the microbubble surface can protect nucleic acids from enzymatic degradation, improve the circulation profile and ultimately increase the drug payload to tissue following ultrasound-mediated microbubble destruction. Most of these formulations demonstrated either high DNA loading capacity or high transfection efficiency. However, effective in vivo gene transfection requires both a high nucleic acid payload and sophisticated packaging to promote intracellular delivery and trafficking to the nucleus.
In this study, we present a method of coupling plasmid DNA to the surface of lipid-based microbubbles using a chemically modified cationic polymer, polyethylenimine (PEI). PEI is a well-established transfection agent due to its high cationic charge, which enables the polymer to bind and condense DNA, promote endocytic uptake in cells, and facilitate endosomal escape of DNA into the cytoplasm by the so-called "proton-sponge" effect (Boussif et al., 1995) . Since it was introduced, PEI has been cited as one of the most potent in vitro non-viral DNA transfection agents (Park et al., 2006; Basarkar and Singh, 2007; Vicennati et al., 2008) . However, efforts towards using PEIbased vectors to deliver DNA in vivo have been less successful. Due to the high cationic charge of the polymer backbone, PEI-based vectors are rapidly cleared from circulation and potentially cytotoxic. The biocompatibility can be dramatically improved by the addition of non-ionic polyethylene glycol (PEG) to ameliorate the surface charge and reduce complement activation (Petersen et al., 2002; Sung et al., 2003; Brus et al., 2004) . Other methods of reducing toxicity have been employed, such as cross linking low-molecular-weight PEI molecules to make biodegradable PEI-based vectors Forrest et al., 2003; Thomas et al., 2005; Wen et al., 2009) . Despite improvements in biocompatibility, the circulation profile of PEI-based DNA vectors remains relatively poor, presumably due to rapid accumulation in the lung, liver, spleen and kidney (Malek et al., 2009) .
MATERIALS AND METHODS
Generation and characterization of polyplex-microbubbles was described in (Sirsi et al., 2012) . Briefly, the lipids used to encapsulate the microbubbles, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2K), and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG2K-Mal), were obtained from Avanti Polar Lipids (Alabasater, AL). Microbubbles were formed by mechanical agitation of the lipid suspension (90 mol% DSPC, 5 mol% DSPE-PEG2K, and 5 mol% DSPE-PEG2K-Mal) in the presence of perfluorobutane (PFB) gas (FluoroMed, Round Rock, TX). DSPE-PEG2K-Mal was varied between 0.5% and 5%, in which case the amount of DSPE-PEG2K was increased so that the DSPE-PEG lipids always comprised 10 mol% of the lipid composition. All lipid stock solutions were dissolved and mixed at the appropriate ratios in chloroform (Sigma-Aldrich) in a sealed 3-mL glass serum vial (Wheaton, Millville, NJ) to 1 mg total lipid per vial. The resulting lipids were dried and re-suspended in 2 mL of 0.01 M PBS buffer containing 10 vol% glycerol and 10 vol% propanediol. The lipid solution was warmed to 60 qC and briefly sonicated to disperse the lipid in a bath sconicator (Branson, Danbury, CT). The air headspace was exchanged with PFB using a custom gas exchange apparatus, and the pressure in the vial was vented briefly to the atmosphere to relieve pressure. The microbubbles were then formed by shaking in a VialMix (Bristol-Myers Squibb, New York, NY). Microbubbles obtained from 5 vials were pooled in a 12-mL syringe. Lipid vesicles and microbubbles less than 4 µm diameter were removed using a centrifugation method similar to Feshitan et al. (Feshitan et al., 2009 ). The microbubble suspension was repeatedly centrifuged at 90 relative centrifugal force (RCF) for 1 minute using a bucket-rotor centrifuge (Model 5804, Eppendorf, Westbury, NY). For every repetition, the microbubble cake was saved and infranatant was discarded. The final microbubble suspension was diluted in PBS buffer (pH 6.5) containing 1 mM EDTA.
Microbubbles were coated with PEG-PEI-SH polymers by covalently coupling the maleimide end-groups on the microbubble surface to the thiol groups on the PEG-PEI-SH polymers. Polymers were dissolved to 10 mg/mL in PBS buffer (pH 6.5) containing 1 mM EDTA. Maleimide bearing microbubbles were added drop-wise to the polymer solution while gently mixing, and the suspension was gently mixed for 24 hours. A molar excess of 10:1 PEI/maleimide ratio was used to prevent aggregation of the microbubbles.
RESULTS
Results were originally presented in (Sirsi et al., 2012) . Figure 1 shows the total DNA loading capacity per unit surface area of the PEI-microbubbles. The loading capacity increased in proportion with maleimide-lipid concentration. This result was consistent with the zeta potential measurements described above: more maleimide led to greater PEI deposition, which in turn led to greater DNA loading. The highest DNA loading capacity of 0.005 pg/µm 2 was greater than previously reported loading capacities of microbubbles formulated with cationic lipids (0.001 pg/µm 2 (Christiansen et al., 2003) , 0.004 pg/µm 2 (Chen et al., 2006) , and 0.001-0.006 pg/µm 2 (Borden et al., 2007) ), and similar to polymer-coated microbubbles assembled by electrostatic layering using cationic polymers (0.004 pg/µm 2 (Lentacker et al., 2006) and 0.010 pg/µm 2 (Borden et al., 2007) for single layers). Here, however, we have PEGylated the complex to increase biocompatibility, and the cationic polymer is covalently attached to the microbubble surface in order to form a more stable polyplex linkage. DNA transfections using a luciferase plasmid were performed on SKNEP-1 tumor-bearing mice using the 5 mol% maleimide PEI-microbubbles. In vivo bioluminescence imaging at 48 hours post-transfection showed sitespecific luciferase expression in the abdominal area flanking the kidney where the tumor was implanted and the ultrasound transducer was applied (Figure 2A ). The photon flux from the tumor area was measured to be over 10-fold higher than the baseline signal from untreated mice (Fig. 2B) . The luciferase expression measured ex vivo was over 40-fold higher in tumor tissue than in heart tissue in animals that received DNA/PEI-microbubbles and ultrasound (Fig. 2C) . No bioluminescence was detected above background in the mice exposed to DNA/PEImicrobubbles without ultrasound by either IVIS or in tumor tissue homogenates. These results showed that both microbubbles and ultrasound were necessary to transfect the tumors, and the transfection was isolated to the tissue exposed to ultrasound. 
CONCLUSIONS
Polyplex-microbubbles were formed by attaching PEI-PEG-SH to maleimide-lipid microbubbles and then loading with plasmid DNA. PEI and DNA loading onto microbubbles was controlled by modulating maleimide concentration in the microbubble shell. The DNA loading capacity was higher for PEI-microbubbles than for cationic lipid-microbubbles. Successful transfection indicated that the DNA/PEI-microbubbles circulated sufficiently long to provide sonoporation in the tumor tissue. These results demonstrate proof-of-principle that the polyplex-loaded bubbles are viable plasmid DNA transfection agents for targeted delivery to tumors in vivo.
